Volume 115, Issue 2 p. 135-139
Clinical articles

Oral misoprostol for the management of incomplete abortion in Ecuador

Rolando Montesinos

Rolando Montesinos

Hospital Gineco-Obstétrico Isidro Ayora, Quito, Ecuador

Search for more papers by this author
Jill Durocher

Corresponding Author

Jill Durocher

Gynuity Health Projects, New York, USA

Corresponding author at: Gynuity Health Projects, 15 E. 26th Street, Suite 801, New York, NY 10010, USA. Tel.: + 1 212 448 1230; fax: + 1 212 448 1260.Search for more papers by this author
Wilfrido León

Wilfrido León

Hospital Gineco-Obstétrico Isidro Ayora, Quito, Ecuador

Search for more papers by this author
Mónica Arellano

Mónica Arellano

Centro Médico de Orientación y Planificación, Quito, Ecuador

Search for more papers by this author
Melanie Peña

Melanie Peña

Gynuity Health Projects, New York, USA

Search for more papers by this author
Ernesto Pinto

Ernesto Pinto

Gynuity Health Projects, New York, USA

Search for more papers by this author
Beverly Winikoff

Beverly Winikoff

Gynuity Health Projects, New York, USA

Search for more papers by this author
First published: 26 August 2011
Citations: 11

Abstract

Objective

To assess the feasibility of introducing misoprostol for the treatment of incomplete abortion in Quito, Ecuador.

Methods

In a randomized prospective study conducted at a large tertiary-level maternity hospital and a private secondary-level clinic between November 2006 and November 2007, women with incomplete abortion were treated with either 600 μg of oral misoprostol (n = 122) or manual vacuum aspiration (MVA) (n = 120). All participants were requested to return for follow-up care on day 7 to determine the success of the treatment and to document their satisfaction with the method and the adverse effects experienced.

Results

Sixteen percent of women (39/242) did not return for their follow-up visit and their outcomes are unknown. Among those who did return, 94% (100/106) of women showed successful completion of abortion after treatment with misoprostol, as compared with 100% (97/97) of women treated with MVA. Most women described their adverse effects after treatment as tolerable (misoprostol, 95%; MVA, 91%). Nearly all women reported being satisfied with their treatment (196/203); there were no differences among the women's reports of satisfaction according to treatment received.

Conclusion

An oral dose of 600 μg of misoprostol was found to be an acceptable and effective non-surgical option for treating incomplete abortion. Clinical trials.gov NCT00674232.